Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6179MR)

This product GTTS-WQ6179MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6179MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8122MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ13338MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ13822MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ1724MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15428MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ8886MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ13709MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ380MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW